Home > Boards > US Listed > Medical - Drugs >

Transgenomic Inc. (TBIO)

Add TBIO Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 2/5/2016 12:04:08 PM - Followers: 31 - Board type: Free - Posts Today: 0


Link to coporate website:

Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.

Colorectal Cancer Testing

Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"

CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).


New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."


Contact Information:
Phone: (402) 452-5437

SEC Filings:

Press Releases:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#900   NSDQ with 30k shares on the bid. TBIO$ alphaInvestor2 02/05/16 12:04:08 PM
#899   what happened? paxgarmana 02/04/16 02:17:45 PM
#898   You said it bro. May be a alphaInvestor2 02/04/16 12:57:59 AM
#897   Nice and quiet here I see..... ledrog_krill 02/03/16 08:32:40 PM
#896   Agreed, I would have been better off shorting alphaInvestor2 01/21/16 03:18:28 AM
#895   This price action is a result of toxic alphaInvestor2 01/20/16 08:56:25 AM
#894   Agreed. Maybe they can finally discover that it laser777 01/14/16 10:31:31 AM
#893   That last bit of news sucked. alphaInvestor2 01/14/16 03:41:03 AM
#892   Merry Christmas all$. TBIO$ alphaInvestor2 12/25/15 03:15:34 PM
#891   Merry X-mas. This thing is getting hot. may money-magnet 12/25/15 08:58:25 AM
#890   Merry Christmas all$. TBIO$ alphaInvestor2 12/23/15 04:20:07 PM
#889   Nice day here at TBIO$. Setting up for alphaInvestor2 12/22/15 05:31:38 PM
#888   Back up to $1. Hopeful for the alphaInvestor2 12/18/15 06:41:05 PM
#887   Up 36% pre market claymore 12/11/15 08:21:07 AM
#886   I would just keep this one on watch. alphaInvestor2 12/03/15 10:16:06 AM
#885   Because this company will change how Cancer is Wopsal101 12/01/15 07:56:19 PM
#884   I just made a pile of money and bradlee 12/01/15 12:48:00 PM
#883   I'm hoping for a merry Christmas with news alphaInvestor2 11/27/15 10:15:24 AM
#882   Super low float here. News of a alphaInvestor2 11/24/15 01:57:32 PM
#881   Universities all over the country are already starting alphaInvestor2 11/24/15 01:51:36 PM
#880   Genetic testing is about to be a multi alphaInvestor2 11/24/15 01:46:58 PM
#879   I'm surprised TBIO hasn't been on more people's alphaInvestor2 11/24/15 10:54:37 AM
#878   TBIO 1.45. swampboots 11/24/15 09:56:00 AM
#877   Low float action. This thing moves on alphaInvestor2 11/24/15 09:35:46 AM
#876   No doubt. Looks like Kinnon is lining alphaInvestor2 11/19/15 11:23:35 AM
#875   Hey Alpha how are you? Been busy as Tstorm 11/19/15 11:17:09 AM
#874   Another day of loading on time and sales. alphaInvestor2 11/16/15 02:40:11 PM
#873   Mr. Kinnon concluded, “Since the start of the alphaInvestor2 11/13/15 05:18:33 PM
#872   Mr. Kinnon continued, “From a financial perspective, this alphaInvestor2 11/13/15 05:15:24 PM
#871   This has very good chances of popping. alphaInvestor2 11/06/15 05:41:35 PM
#870   Paint job in the opposite direction IMO. Something alphaInvestor2 11/06/15 04:26:09 PM
#869   See Kinnon. This thing can climb quick alphaInvestor2 11/05/15 09:48:07 AM
#868   I agree but at least this should keep Tstorm 11/05/15 09:21:07 AM
#867   It is good news but not the news alphaInvestor2 11/05/15 09:16:06 AM
#866   NEWS out! Tstorm 11/05/15 09:10:35 AM
#865   Kinnon needs to make a profitable deal. alphaInvestor2 11/02/15 10:55:01 PM
#864   We need to break $1.00 tomorrow... Tstorm 11/02/15 06:40:55 PM
#863   Glad to see more accumulation today. alphaInvestor2 11/02/15 05:53:55 PM
#862   This is a DISASTER!!!! Tstorm 10/30/15 11:54:05 PM
#861   Wow. This is not pretty alphaInvestor2 10/30/15 03:16:15 PM
#860   Biotech setting up for a rebound - Tstorm 10/30/15 08:57:29 AM
#859   .81 bid showing... UNREAL! Tstorm 10/29/15 01:52:14 PM
#858   Game Plan..... laser777 10/29/15 01:25:53 PM
#857   Another boring day at TBIO. Only two alphaInvestor2 10/29/15 08:58:04 AM
#856   New low on the chart... SAD, very SAD Tstorm 10/27/15 03:02:10 PM
#855   As i have stated for a month now. Tstorm 10/27/15 03:00:19 PM
#854   Someone is loading again today. I think alphaInvestor2 10/27/15 01:23:03 PM
#853   I couldnt agree more! Tstorm 10/27/15 11:15:29 AM
#852   No one cares about all these little news alphaInvestor2 10/27/15 09:38:35 AM
#851   I want them to announce a business deal alphaInvestor2 10/27/15 08:50:39 AM